References
Original article
Sanyal, A. et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet https://doi.org/10.1016/S0140-6736(18)31785-9 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Morris, A. Potential treatment strategy for NASH. Nat Rev Endocrinol 15, 129 (2019). https://doi.org/10.1038/s41574-019-0162-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-019-0162-1
- Springer Nature Limited
This article is cited by
-
Fat mass and obesity–associated protein promotes liver steatosis by targeting PPARα
Lipids in Health and Disease (2022)
-
Serum FGF21 levels are altered by various factors including lifestyle behaviors in male subjects
Scientific Reports (2021)